EGFR and lung adenocarcinoma: In a subsequent phase IIB trial (LUX-Lung 7 [12]) afatinib conferred a significant benefit in prolonging PFS and time to treatment failure, but not overall survival (OS), compared to first-line treatment with gefitinib in patients with advanced EGFR mutation-positive lung adenocarcinoma.